Svenja Neumann

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

Hermann Einsele, Carsten Reinhardt, Thomas Burmeister, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.

Albrecht Reichle, Hermann Einsele, Monika Brüggemann, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.

Andreas Wolf, Dirk Nagorsen, Monika Brüggemann, 2012, Blood.